Tesamorelin

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of all 44 amino acids of native GHRH with a trans-3-hexenoic acid moiety conjugated to the tyrosine residue at position 1 via a carbamate linker. This modification yields a molecular weight of approximately 5,136 Da. The trans-3-hexenoic acid group sterically shields the N-terminal region from dipeptidyl peptidase IV (DPP-IV) cleavage, which is the primary route of GHRH degradation in vivo, resulting in meaningfully improved metabolic stability compared to native GHRH and sermorelin.

Tesamorelin binds the GHRH receptor on anterior pituitary somatotrophs with affinity comparable to native GHRH. Like sermorelin, it activates the Gs/adenylyl cyclase/cAMP/PKA signaling cascade, stimulating both GH gene transcription and vesicular GH release. The key pharmacological difference is duration of action: the trans-3-hexenoic acid modification extends the effective half-life, producing a more sustained and reproducible GH pulse. Pituitary negative feedback via somatostatin and IGF-1 remains intact, preserving the physiological safety margin of GHRH-based approaches.

Tesamorelin is the only GHRH analog to achieve full FDA approval for a body composition indication. Marketed as Egrifta, it was approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The approval was based on two key Phase 3 randomized, double-blind, placebo-controlled trials (LIPO-010 and LIPO-011) enrolling a combined 816 patients. After 26 weeks, tesamorelin reduced visceral adipose tissue (VAT) by 15-18% as measured by CT scan, compared to a 5% increase in placebo groups (p < 0.001). Trunk fat, waist circumference, and triglyceride levels all improved significantly.

Beyond visceral fat reduction, tesamorelin has demonstrated cognitive benefits in clinical trials. A study published in Neurology by Stanley et al. enrolled 137 healthy older adults (ages 55-87) and found that 20 weeks of tesamorelin improved verbal memory (p = 0.03) and executive function compared to placebo. These effects are thought to be mediated by the neurotrophic actions of IGF-1, which crosses the blood-brain barrier and activates neuronal survival and synaptic plasticity pathways. A separate trial in HIV-positive adults showed similar cognitive improvements.

Pharmacokinetically, tesamorelin reaches peak plasma concentration approximately 15-30 minutes after subcutaneous injection. The elimination half-life is approximately 26-38 minutes, substantially longer than sermorelin (10-20 minutes). Bioavailability after subcutaneous injection is approximately 4-5%, which is typical for peptide therapeutics. The recommended clinical dose used in the Egrifta label is 2 mg administered subcutaneously once daily.

The safety profile of tesamorelin is well documented through its FDA approval process and post-marketing surveillance. The most common adverse reactions reported in clinical trials were injection site reactions (erythema, pruritus, pain) occurring in approximately 8-13% of patients. Other reported effects included arthralgia (3.3%), peripheral edema (2.2%), and myalgia (1.5%). Tesamorelin did not significantly alter glucose homeostasis or HbA1c in the key trials, though monitoring is recommended in patients with diabetes.

For reconstitution, lyophilized tesamorelin should be reconstituted with the sterile water diluent provided or with bacteriostatic water. The reconstituted solution should be used immediately or stored at 2-8 degrees C for up to 24 hours per the Egrifta label. Lyophilized vials should be stored refrigerated. For research-grade material, lyophilized powder is stable at -20 degrees C for extended periods.

Tesamorelin remains the gold standard among GHRH analogs for published evidence of visceral fat reduction. Its FDA approval provides a level of clinical validation that few research peptides possess. Ongoing research continues to explore its potential applications in nonalcoholic fatty liver disease (NAFLD), where a 2019 trial published in Lancet HIV demonstrated a 32% relative reduction in hepatic fat fraction over 12 months.